<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03962543</url>
  </required_header>
  <id_info>
    <org_study_id>MEK-NF-201</org_study_id>
    <nct_id>NCT03962543</nct_id>
  </id_info>
  <brief_title>MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas</brief_title>
  <acronym>ReNeu</acronym>
  <official_title>A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SpringWorks Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SpringWorks Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates mirdametinib (PD-0325901) in the treatment of symptomatic inoperable&#xD;
      neurofibromatosis type-1 (NF1)-associated plexiform neurofibromas (PNs). All participants&#xD;
      will receive mirdametinib (PD-0325901).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neurofibromas are benign peripheral nerve sheath tumors, which are classified as plexiform&#xD;
      neurofibromas (PNs) if they extend longitudinally along a nerve and involve multiple&#xD;
      fascicles. PNs are a major cause of morbidity and disfigurement in individuals with NF1, and&#xD;
      as the tumor growth progresses, can cause a multitude of clinical deficits including pain and&#xD;
      impaired physical function. PNs have the potential to undergo malignant transformation to&#xD;
      Malignant Peripheral Nerve Sheet Tumors (MPNST).&#xD;
&#xD;
      Mirdametinib (PD-0325901) is an orally delivered, highly selective small-molecule inhibitor&#xD;
      of the dual specificity kinases, MEK1 and MEK2 (MAPK/ERK Kinase) which prevents the&#xD;
      phosphorylation and subsequent activation of mitogen-activated protein kinase (MAPK).&#xD;
&#xD;
      Previous studies of mirdametinib (PD-0325901) demonstrated PN shrinkage and sustained&#xD;
      inhibition of pERK. Reduced tumor volume indicated that cell proliferation or cell death may&#xD;
      be altered in PNs with administration of mirdametinib (PD-0325901).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 6, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All participants will receive mirdametinib (PD-0325901) at a dose of 2 mg/m^2 twice daily (maximum dose of 4 mg twice daily), calculated based on body surface area. Dose will be administered in a 3-week on, 1-week off schedule.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete or partial response rate compared to baseline. Partial response is defined as a ≥ 20% reduction in target tumor volume.</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Response will be determined by a blinded centralized review of volumetric MRI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events.</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Adverse events will be assessed according to toxicities graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) for participants who meet criteria for objective response rate.</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Response will be determined by a blinded centralized review of volumetric MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on quality of life (QOL) as measured by the Pediatric Quality of Life Inventory (PedsQL), Acute version.</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The PedsQL consists of a 23-item core measure of global QOL that can be completed in approximately 5 minutes. There are four subscales: physical functioning, emotional functioning, social functioning and school/work functioning. Participants ≥ 5 years of age complete an age-appropriate self-report; and parents/guardians of children ages 2-17 complete a parent proxy report of the age-specific QOL. The recall period is 7 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in pain as measured by the Numeric Rating Scale-11 (NRS-11).</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The NRS-11 is a self-reported 11-point numerical scale that assesses pain severity. Participants ≥ 8 years of age are asked to select a number from 0 (no pain) to 10 (worst pain you can imagine) that best describes their worst pain. The recall period is 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in pain as measured by the Pain Interference Index (PII).</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The PII assesses relevant aspects of one's life, including pain interference with activities, spending time with family/friends, mood, sleep and attention. Participants ≥ 6 years of age complete a self-report, and parents/guardians of children age 6-17 complete a parent proxy report. The recall period is 24 hours.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from Baseline in physical function status as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS): physical function/mobility/upper extremity short forms (8a and 8b).</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>PROMIS measures capability of physical functioning, with questions related to daily activities. Participants ≥ 18 years of age complete a self-report of physical function. Participants 8-17 years of age complete a self-report of physical function in the upper extremity or lower extremity (mobility), depending on location of the PN. Parents/guardians of children ages 2-17 complete a parent proxy report corresponding to the pediatric version. The recall period is 7 days.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in localized strength.</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>If motor dysfunction or weakness is evident, strength of the affected muscle groups will be measured by dynamometer and assessed by a muscle grading scale.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in range of motion of PN-associated functional impairment.</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>If motor dysfunction or weakness is evident, range of motion of the affected areas and/or joints will be measured by a goniometer.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in endurance.</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>If airway or lower extremity motor dysfunction is evident, endurance will be measured by completion of a 6-minute walking test.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to Response defined as the time between first dose and the first date of objective response.</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Response will be determined by a blinded centralized review of volumetric MRI.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to progression, from the first dose to the date of a ≥ 20% increase in tumor volume.</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Evidence of progression or tumor growth will be determined by a blinded centralized review of volumetric MRI.</description>
  </other_outcome>
  <other_outcome>
    <measure>Progression Free Survival, defined as the time in months from the first dose to the date of a ≥ 20% increase in tumor volume or death.</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Evidence of progression or tumor growth will be determined by a blinded centralized review of volumetric MRI.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline in PN-associated disfigurement using standardized photography, centrally reviewed.</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>For participants with a PN that is visible and amenable to photography, changes in visible tumor aspects will be evaluated by a centralized reviewer.</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of tumor response to levels of pERK and biomarkers indicative of inhibition of downstream targets of MEK (eg, ERK phosphorylation).</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Measured in tumor biopsies in participants ≥ 18 years of age.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Plexiform Neurofibroma</condition>
  <condition>Neurofibromatosis Type 1 (NF1)</condition>
  <arm_group>
    <arm_group_label>Mirdametinib (PD-0325901)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mirdametinib (PD-0325901) capsule or dispersible tablet 2 mg/m^2 (maximum dose of 4 mg) by mouth twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirdametinib (PD-0325901) oral capsule or dispersible tablet</intervention_name>
    <description>Mirdametinib (PD-0325901) capsule or dispersible tablet</description>
    <arm_group_label>Mirdametinib (PD-0325901)</arm_group_label>
    <other_name>PD-0325901</other_name>
    <other_name>Mirdametinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Participant has documented NF1 mutation or a diagnosis of neurofibromatosis type 1&#xD;
             (NF1) using National Institute of Health (NIH) Consensus Conference criteria inclusive&#xD;
             of the presence of a plexiform neurofibroma (PN).&#xD;
&#xD;
          -  Participant has a PN that is causing significant morbidity.&#xD;
&#xD;
          -  Participant has a PN that cannot be completely surgically removed.&#xD;
&#xD;
          -  Participant has a target tumor that is amenable to volumetric MRI analysis.&#xD;
&#xD;
          -  Participant is willing to undergo a tumor biopsy pre and post treatment if ≥ 18 years&#xD;
             of age.&#xD;
&#xD;
          -  Participant has adequate organ and bone marrow function.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Participant has abnormal liver function or history of liver disease.&#xD;
&#xD;
          -  Participant has lymphoma, leukemia or any malignancy within the past 5 years (except&#xD;
             for resected basal/squamous skin carcinomas without metastases within 3 years).&#xD;
&#xD;
          -  Participant has breast cancer within 10 years.&#xD;
&#xD;
          -  Participant has active optic glioma or other low-grade glioma requiring treatment.&#xD;
&#xD;
          -  Participant has abnormal QT interval corrected or other heart disease within 6 months.&#xD;
&#xD;
          -  Participant has a history of retinal pathology, risk factors for retinal vein&#xD;
             occlusion or has a history of glaucoma.&#xD;
&#xD;
          -  Participant has known malabsorption syndrome or gastrointestinal conditions that would&#xD;
             impair absorption of mirdametinib (PD-0325901).&#xD;
&#xD;
          -  Participant has received NF1 PN-targeted therapy within 45 days.&#xD;
&#xD;
          -  Participant previously received or is currently receiving therapy with mirdametinib&#xD;
             (PD-0325901) or any other MEK1/2 inhibitor.&#xD;
&#xD;
          -  Participant has received radiation therapy within 6 months or has received radiation&#xD;
             to the orbit at any time.&#xD;
&#xD;
          -  Participant is unable to undergo or tolerate MRI.&#xD;
&#xD;
          -  Participant has active bacterial, fungal or viral infection.&#xD;
&#xD;
          -  Participant has experienced other severe acute or chronic medical or psychiatric&#xD;
             conditions within 1 year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Associate Director Clinical Development</last_name>
    <phone>919-790-1002</phone>
    <email>clinical@springworkstx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Senior Manager Clinical Operations</last_name>
    <phone>919-790-1002</phone>
    <email>clinical@springworkstx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham/Children's of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aakruti Sharma, SC</last_name>
      <email>asharma@peds.uab.edu</email>
    </contact>
    <investigator>
      <last_name>Katie Metrock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mayra Fernandez, SC</last_name>
      <email>tornel.mayra@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Radhika Dhamija, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Redinger, SC</last_name>
      <email>redingercatherinel@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Bielamowicz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jasmine Pauly</last_name>
      <email>jpauly@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Nathan Robison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Oncology Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emese Filka, SC</last_name>
      <email>EFilka@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Phioanh (Leia) Nghiemphu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California - Irvine Health</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868-3201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehir Tharani</last_name>
      <email>mehirt@hs.uci.edu</email>
    </contact>
    <investigator>
      <last_name>Daniela Bota, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorian Chan</last_name>
      <email>dchan@choc.org</email>
    </contact>
    <investigator>
      <last_name>Carol Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital Stanford</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Velasco, SC</last_name>
      <email>ericav@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Cynthia Campen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California - Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Gam, SC</last_name>
      <email>sgam@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Reuben Antony, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Mettetal, SC</last_name>
      <email>ashley.mettetal@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Nicholas Foreman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours A. I. duPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Bertz, SC</last_name>
      <email>debra.bertz@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Gurcharanjeet Kaur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Krisanda, SC</last_name>
      <email>ekrisanda@childrensnational.org</email>
    </contact>
    <investigator>
      <last_name>Lindsay Kilburn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida Clinical Research Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Segura</last_name>
      <email>julie.segura@neurology.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Hans H Shuhaiber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nicklaus Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damaris Rodriguez, SC</last_name>
      <email>Damaris.Rodriguez@Nicklaushealth.org</email>
    </contact>
    <investigator>
      <last_name>Ziad Khatib, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AdventHealth Pediatric Oncology Hematology at Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Hedrick, SC</last_name>
      <email>pamela.hedrick@adventhealth.com</email>
    </contact>
    <investigator>
      <last_name>Fouad Hajjar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orlando Health, Inc.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Spinelli, SC</last_name>
      <email>Jennifer.Spinelli@orlandohealth.com</email>
    </contact>
    <investigator>
      <last_name>Ana Aguilar-Bonilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivanna Leon</last_name>
      <email>ileon3@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Stacie Stapleton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaquila McCauley, SC</last_name>
      <email>shaquila.mccauley@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Sepideh Mokhtari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta - Center for Advanced Pediatrics</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bethany Watson</last_name>
      <email>Bethany.watson@choa.org</email>
    </contact>
    <investigator>
      <last_name>David Wolf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois Hospital and Health Systems</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marisol Vega, SC</last_name>
      <email>vegam35@uic.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kristen Kitsch</last_name>
      <email>kkitsc2@uic.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mary Lou Schmidt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Centers</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Mackenzie, SC</last_name>
      <email>cmackenzie@peds.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>James Tonsgard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IU Health Brain Tumor Infusion Clinic</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Mazurczyk, SC</last_name>
      <email>jmazurcz@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Kathryn Nevel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals &amp; Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen Austin, SC</last_name>
      <email>maureen-austin@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Alpa Sidhu, MBBS, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kosair Charities Pediatric Clinical Research Unit</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Pate, SC</last_name>
      <email>karen.pate@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Alexander Asamoah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan CS Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanna Ramos, SC</last_name>
      <email>jramos@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Andrea Franson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josh Alton, SC</last_name>
      <email>jalton2@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Tobias Walbert, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota/Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Elling, SC</last_name>
      <email>relling@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher Moertel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Bartz, SC</last_name>
      <email>bartz.megan@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Dusica Babovic-Vuksanovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine-Siteman Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Erhardt, SC</last_name>
      <email>eerica@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Brian Van Tine, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Univeristy Medical Center</name>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <zip>07503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JoAnne Lamacchia, SC</last_name>
      <email>lamacchiaj@sjhmc.org</email>
    </contact>
    <investigator>
      <last_name>Punita Gupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Abrey, SC</last_name>
      <email>abreyk@amc.edu</email>
    </contact>
    <investigator>
      <last_name>Lauren Weintraub, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital at Montefiore</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette Pedro, SC</last_name>
      <email>annette.pedro@einsteinmed.org</email>
    </contact>
    <investigator>
      <last_name>Nagma Dalvi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC Medical Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yulissa Gonzalez, SC</last_name>
      <email>yulissa_gonzalez@neurology.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Timothy R. Gershon, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Walter, SC</last_name>
      <email>ashley.walter@duke.edu</email>
    </contact>
    <investigator>
      <last_name>David Van Mater, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Wilson, SC</last_name>
      <email>wilso4sh@ucmail.uc.edu</email>
    </contact>
    <investigator>
      <last_name>Soma Sengupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Backus, SC</last_name>
      <email>Lori.backus@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Brian Weiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janette Gortz</last_name>
      <email>GORTZJ@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Neha Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jayme Beinlich, SC</last_name>
      <email>jayme.beinlich@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Ryan Roberts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center, Jimmy Everest Center for Cancer and Blood Disorders in Children</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haley Jones, SC</last_name>
      <email>haley-jones@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Rene McNall-Knapp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Huddleston, SC</last_name>
      <email>huddlesa@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Prakash Ambady, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Repine</last_name>
      <email>mcmimj2@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Julia Meade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry-Joyce Cancer Clinic</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VICC Clinical Trials Reporting Program</last_name>
      <phone>800-811-8480</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dreaux Abe, SC</last_name>
      <email>dreaux.abe@childrens.com</email>
    </contact>
    <investigator>
      <last_name>Laura J Klesse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Rubalcada</last_name>
      <email>alice.rubalcada@cookchildrens.org</email>
    </contact>
    <investigator>
      <last_name>Sibo Zhao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abram Escobedo</last_name>
      <email>AFEscobedo@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Zsila Sadighi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah, Center for Clinical and Translational Sciences</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Bailey, SC</last_name>
      <email>carrie.bailey@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>David Viskochil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UVA Health, Division of Neuro-Oncology</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Woodburn</last_name>
      <email>cjw4v@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>David Schiff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of The King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terrie Karras Conklin, SC</last_name>
      <email>terrie.conklin@chkd.org</email>
    </contact>
    <investigator>
      <last_name>Sarah Chagnon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center - Cherry Hill Campus</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>MACC Fund Research Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronica Seher</last_name>
      <email>vseher@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Nathan Schloemer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.reneu-nf1clinicaltrial.com</url>
    <description>Study-specific website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 12, 2019</study_first_submitted>
  <study_first_submitted_qc>May 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2019</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neurofibromatoses</keyword>
  <keyword>Neurofibromatosis 1</keyword>
  <keyword>Plexiform Neurofibroma</keyword>
  <keyword>PD-0325901</keyword>
  <keyword>MEK Inhibitor</keyword>
  <keyword>Neurofibroma</keyword>
  <keyword>Mirdametinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Neurofibromatosis 1</mesh_term>
    <mesh_term>Neurofibroma</mesh_term>
    <mesh_term>Neurofibroma, Plexiform</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

